Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

170.08 +0.12 (+0.07%)

Streaming Delayed Price Updated: 12:38 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

27 28 Next >

FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities ↗

March 10, 2023

Via Benzinga

Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births ↗

March 08, 2023

Via Benzinga

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

Retail And Regional Banks Will Call The Shots ↗

March 06, 2023

The 23-month moving average or a 2-year business cycle is particularly important this year after a big up then down year-looms large.

Via Talk Markets

The Economic Modern Family Ready To Howl? ↗

March 05, 2023

As we ended the trading week, there were a few other “worms” that appeared in the market soil. They too seemed to awaken from hibernation as the indices’ prices rose. Are the components of the Economic...

Via Talk Markets

Bullish Reversals ↗

March 02, 2023

Agricultural commodities have fallen a lot lately. Food supply and shortages remain a concern going into the spring and summer growing seasons.

Via Talk Markets

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

Century Aluminum Pops Up As Bullish ↗

February 27, 2023

Given the recent sell-off in aluminum, copper, and steel, industrial metals remain overall outperformers.

Via Talk Markets

Stock Market Forecast: Stocks May Drop Further As Rates Rise ↗

February 26, 2023

This week will be full of economic insights, but the big data will be the ISM manufacturing and services indexes. However, I think these two reports are unlikely to do much to reverse the current trend...

Via Talk Markets

No Landing - Sugar Coated Words For Stagflation? ↗

February 22, 2023

SPX failed the 23-month moving average or 2-year business cycle, which if clears, signals a softer landing. Yet, it held the pivotal 3900 ahead of the Fed, signaling a no landing.

Via Talk Markets

Is The Whole Country Buying Teslas And Eating At Wingstop? ↗

February 15, 2023

XRT is making lower highs each of the last 3 weeks but also has found a basis of support at 68.00.

Via Talk Markets

Tuesday Talk: My Sweet CPI ↗

February 14, 2023

The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday.

Via Talk Markets

Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers ↗

February 13, 2023

Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.

Via Talk Markets

ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood ↗

February 13, 2023

Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.

Via InvestorPlace

2-Year Business Cycles Matter In Commodities ↗

February 08, 2023

Gold is above the 23-month MA and the 2-year business cycle.

Via Talk Markets

2-Year Business Cycles Matter In This Market ↗

February 07, 2023

In October, IWM held the 80-month and got us believing that a recession would be averted. Now, the market literally hangs in the balance between a longer-term and a shorter-term business cycle.

Via Talk Markets

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January ↗

January 30, 2023

Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.

Via Talk Markets

What Are The Equities Market’s Warning Signs? ↗

January 30, 2023

The 52-week New High / New Low ratio for the Nasdaq Composite has actually begun to deteriorate, a clear Risk-Off indication for the short term.

Via Talk Markets

Inflation, What Inflation? ↗

January 29, 2023

We typically have a song or two in our heads. After all, watching ticks is musical and has a lot of different beats. And typically, those songs turn into parodies.

Via Talk Markets

Global Stocks: Breaking Out? ↗

January 28, 2023

The S&P 500 is attempting to clear what has been an insurmountable trendline dating back to January 2022.

Via Talk Markets

The 3 Best Biotech Stocks Under $1 to Buy for January ↗

January 26, 2023

Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.

Via InvestorPlace

Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗

January 06, 2023

Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.

Via Benzinga

SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗

January 06, 2023

Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro ↗

December 19, 2022

The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.

Via Talk Markets

Tarsus Added to NASDAQ Biotechnology Index

December 16, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Small Caps Vs Large Caps: Who Is Leading? ↗

December 07, 2022

Clearly, large-cap stocks have been leading with the Dow Jones down the last year to date, but even though the selling pressure has been constant, trading volume has been anemic.

Via Talk Markets

Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades' ↗

December 05, 2022

The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.